佰泽医疗通过上市聆讯：年营收近12亿 经调整净利1250万

Core Viewpoint - Baize Medical Group is preparing for an IPO on the Hong Kong Stock Exchange, focusing on providing comprehensive cancer care services throughout the entire treatment cycle [2][3]. Financial Performance - Baize Medical's revenue for 2022, 2023, and 2024 is projected to be RMB 8.03 billion, RMB 10.72 billion, and RMB 11.89 billion respectively, with gross profits of RMB 795.6 million, RMB 1.78 billion, and RMB 2.08 billion [5][6]. - The company reported operating profits of RMB -38.09 million, RMB 22.43 million, and RMB 34.99 million for the years 2021, 2022, and 2023 respectively, with net losses of RMB 75.52 million, RMB 24.41 million, and RMB 3.56 million [8][9]. - By 2024, Baize Medical expects to achieve an adjusted net profit of RMB 12.5 million, marking a turnaround from previous losses [10]. Business Segments - In 2024, hospital business revenue is expected to reach RMB 9.52 billion, accounting for 80.1% of total revenue, with inpatient services contributing RMB 5.44 billion (45.8%) and outpatient services RMB 4 billion (33.7%) [6][7]. - Revenue from the supply of pharmaceuticals, medical devices, and consumables is projected to be RMB 1.91 billion, representing 16% of total revenue in 2024 [7]. Cash Flow and Assets - As of December 31, 2024, Baize Medical's cash and cash equivalents are expected to total RMB 294.24 million, with net cash from operating activities of RMB 168.54 million [11]. Shareholding Structure - Xu Xu is the major shareholder, holding 57.56% of the shares through Bayway Fund L.P. Other significant shareholders include Shanghai Zhenghe Sheng Enterprise Management and Xuxi Holding [12][16].